CompletedPhase 2/3

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

Germany36 participantsStarted 2015-08-15

Plain-language summary

The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subject completed participation in the TR03 study Exclusion Criteria: * Medical condition or other factors that in the opinion of the Investigator may interfere with the conduct of the study. * Subject is a pregnant or lactating female

What they're measuring

Overall Incidence and Nature of Treatment Emergent Adverse Events (TEAEs)

Timeframe: 50 weeks

Trial details

NCT IDNCT02174432

SponsorTrevi Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-09-03

Results submitted2020-08-06

View on ClinicalTrials.gov More Prurigo Nodularis trials